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ABSTRACT 
Background: The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE) 
found that the prevalence of cardiovascular events (CVEs) was significantly 
lower with standard-dose (10-20 mg/d) pravastatin treatment compared with 
low-dose (5 mg/d) pravastatin treatment in elderly: (aged >60 years) Japanese 
patients with hypercholesterolemia. Small differences in on-treatment total cho- 
lesterol and low-density lipoprotein cholesterol (LDL-C) levels between the 
2 dose groups in the PATE study were associated with significant differences in 
CVE prevalence. However, the reasons for these differences have not been de- 
termined. How sex and age differences influence the effectiveness of pravastatin 
also remains unclear. 
Objectives: The aims of this study were to determine the relationship 
between reduction in LDL-C level and CVE risk reduction in the PATE study and 
to assess the effects of sex and age on the effectiveness of pravastatin treat- 
ment (assessed using CVE risk reduction). 
Methods: In this post hoc analysis, Cox regression analysis was performed 
to study the relationship between on-treatment (pravastatin 5-20 mg/d) LDL-C 
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level and CVE risk reduction using age, sex, smoking status, presence of dia- 
betes mellitus and/or hypertension, history of cardiovascular disease (CVD), 
and high-density lipoprotein cholesterol level as adjustment factors. To explore 
risk reduction due to unspecified mechanisms other than LDL-C reduction, an 
estimated Kaplan-Meier curve from the Cox regression analysis was calculated 
and compared with the empirical (observed) Kaplan-Meier curve. 
Results: A total of 665 patients (527 women, 138 men; mean [SD] age, 72.8 
[5.7] years) were enrolled in PATE and were followed up for a mean of 3.9 years 
(range, 3-5 years). Of those patients, 50 men and 173 women were _>75 years of 
age. Data from 619 patients were included in the present analysis. In the calcu- 
lation of model-based Kaplan-Meier curves, data from an additional 32 patients 
were excluded from the LDL-C analysis because there were no data on pretreat- 
ment LDL levels; hence, the data from 587 patients were analyzed. A reduction 
in LDL-C level of 20 mg/dL was associated with an estimated CVE risk reduction 
of 24.7% (hazard ratio [HR] = 0.753; 95% CI, 0.625-0.907; P -- 0.003). Risk was 
reduced by 22.2% in patients aged <75 years (FIR = 0.778; 95% CI, 0.598-1.013; 
P = NS) and 29.9% in patients aged _>75 years (HR = 0.701; 95% CI, 0.526-0.934; 
P = 0.015). The risk reductions were 19.8% in women (FIR -- 0.802; 95% CI, 
0.645-0.996; P-- 0.046) and 35.8% in men (FIR -- 0.642; 95% CI, 0.453-0.911; P-- 
0.013). The risk reduction was 32.4% in patients without a history of CVD at 
enrollment (FIR = 0.676; 95?/o CI, 0.525-0.870; P = 0.002) and 15.1% in those with 
a history of CVD (FIR = 0.849; 95% CI, 0.630-1.143; P-- NS). The estimated Kaplan- 
Meier curve strongly suggested that the effects of pravastatin were only par- 
tially associated with changes in LDI_,-C level. 
Condusions: The results from this post hoc analysis suggest hat prava- 
statin 5 to 20 mg/d might elicit CVE risk reduction by mechanisms other than 
cholesterol-lowering effects alone. They also suggest that pravastatin treatment 
might be effective in reducing the risk for CVEs in both female and male patients 
aged _>75 years. (Curr Ther Res Clin Exp. 2006;67:241-256) Copyright © 2006 
Excerpta Medica, Inc. 
Key words: PATE study, elderly, hypercholesterolemia, pravastatin, PROBE 
trial, post hoc. 
INTRODUCTION 
Hypercholesterolemia is an established risk factor for cardiovascular events 
(CVEs). 1 The Lipid Research Clinics Coronary Primary Prevention Trial 
(LRCCPPT), 2-4 using the bile-acid sequestrant cholestyramine, and the West 
of Scotland Coronary Prevention Study (WOSCOPS), 5-7 using the 3-hydroxy- 
3-methylglutaryl coenzyme A reductase inhibitor pravastatin, both found 
that successful treatment (low-density lipoprotein cholesterol [LDL-C] reduc- 
tions were 20.3% in LRCCPPT and 26% in WOSCOPS) of hypercholesterolemia 
significantly reduced the risk for CVEs in the context of primary prevention. 
However, in both of those trials, patients aged >65 years were excluded; 
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therefore, the benefits of cholesterol-reduction treatment in older patients 
remained unclear. 
In a post hoc analysis 8 of the Scandinavian Simvastatin Survival Study 
(4S), 9 which included 4444 patients aged 35 to 69 years with coronary heart 
disease (CHD) whose serum total cholesterol (TC) levels were in the range 
of 212 to 309 mg/dL, the effects of simvastatin treatment were analyzed in 
2 patient subgroups: those aged <65 years and those aged _>65 years at 
enrollment. Mean changes in serum lipid levels were similar in the 2 sub- 
groups. In patients aged ___65 years, the relative risk of clinical events in 
simvastatin-treated patients compared with patients in the placebo group 
was as follows: all-cause mortality, 0.66 (95% CI, 0.48-0.90); CHD mortality, 
0.57 (95% CI, 0.39-0.83); and major coronary events, 0.66 (95% CI, 0.52-0.84). 
Because the mortality rate in patients participating in 4S increased (all- 
cause and CHD mortality rates in the simvastatin group of patients 
>65 years of age were 12.9% and 8.5%, respectively; those <65 years of age 
were 6.8% and 3.4%, respectively) with age, the absolute risk reduction for 
both all-cause and CHD mortality in patients receiving simvastatin was twice 
as great in the ->65-year subgroup than in the subgroup aged <65 years. 
A subanalysis of the effects of age 1° was also carried out in the Cholesterol 
And Recurrent Events (CARE) trial, n In this secondary prevention trial, 4159 pa- 
tients aged 21 to 75 years with a history of myocardial infarction 0VID and 
serum TC levels in the mildly elevated range (mean, 209 mg/dL) were random- 
ized to receive daily pravastatin or placebo for a median follow-up period of 
5 years. Among the subset of patients aged >65 years in the pravastatin arm, the 
5-year incidence rates of major coronary events (defined in that study as coro- 
nary death, nonfatal MI, angioplasty, and coronary artery bypass graft) and 
stroke were reduced by 39% (P = 0.001) and 40% (P = 0.03), respectively, com- 
pared with 13% (95% CI, -8 to 31; P = NS) and 20% (95% CI, -36 to 53; P = NS), 
respectively, in patients aged <65 years. Those results suggest hat, at least in 
the secondary prevention setting, pharmacologic cholesterol-reduction treat-
ment is beneficial in elderly patients. 
Based on the results of those earlier trials in nonelderly patients, it was 
clear that a large-scale clinical intervention trial similar to WOSCOPS was 
needed to determine the clinical significance for primary and secondary 
prevention of CVE with hypercholesterolemia in elderly patients. Such a 
trial would accomplish this by determining whether hypercholesterolemia 
is a risk factor for CVEs in elderly patients and whether the successful treat- 
ment of hypercholesterolemia in these patients reduces the occurrence of 
CVEs. The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE), 12 in 
which 52 institutions in Japan participated, was the first randomized, open- 
label, blind-evaluation, clinical trial specifically designed to investigate the 
effects of lowering serum cholesterol levels on the risk for CVEs in elderly 
patients with hypercholester01emia treated with low-dose (in Japan: 5 mg/d) 
or standard-dose (in Japan: 10-20 mg/d) pravastatin. 13
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The major findings of the PATE study 12 have been reported elsewhere. Briefly, 
a total of 665 patients (527 women, 138 men) aged _>60 years (mean [SD] age, 
72.8 [5.7] years) with or without cardiovascular disease (CVD) (177 and 488 patients, 
respectively) whose serum TC levels were in the range of 220 to 280 mg/dL (mean 
[SD], 253 [15] mg/dL) were randomized to receive low- or standard-dose pravastatin 
treatment over a 3- to 5-year (mean, 3.9 years) follow-up period. The mean daily 
doses of pravastatin in the low-dose and standard-dose groups were 4.5 mg and 
8.3 rag, respectively. Mean (SD) serum TC and LDL-C levels significantly decreased 
by 11% to 13% (from 253 [15] to 218 [28] mg/dL) and by 17% to 20% (from 164 [23] 
to 131 [27] mg/dL), respectively, in the low-dose group and by 15% to 17% (from 
253 [15] to 211 [27] mg/dL) and 23% to 26% (from 166 [25] to 127 [27] mg/dL), 
respectively (all, P < 0.001), in the standard-dose group between 3 months and 
3 years after the initiation of treatment. The prevalence of CVEs was significantly 
lower in the standard-dose group than in the low-dose group (generalized Wilcoxon 
test, P = 0.046; log-rank test, P = NS; risk ratio, 0.67; 95% CI, 0.42-1.07). 12 
It is unclear how the small significant differences observed in on-treatment 
TC and LDL-C levels between the 2 groups in the PATE study 12 resulted in signifi- 
cant differences in CVE risk reduction and how age and sex differences might 
have influenced the effects of pravastatin treatment. Subanalyses in WOSCOPS 14 
and the CARE 15 trial reported that no relationship existed between the magni- 
tude of cholesterol lowering and the rate of CVEs with pravastatin. In the 
WOSCOPS report, patients who received the most benefit in terms of risk reduc- 
tion had a mean LDL-C reduction of 24%; further decreases in LDL-C levels were 
not associated with additional reductions in the risk for CVEs. Furthermore, 
among patients in both the placebo and pravastatin groups from the WOSCOPS 
study, whose LDL-C levels were in the range of 140 to 180 mg/dL throughout the 
study, those receiving pravastatin had a 36% lower risk for CVEs than those 
receiving placebo. The risks associated with placebo treatment were similar 
to those estimated using the Framingham risk model, ~6,17 whereas the risks 
observed in the pravastatin group were overestimated by ~31% using the same 
model. Therefore, pravastatin treatment reduced the risk for CVEs by a mecha- 
nism in addition to LDL-C reduction. Similar results were observed in the analy- 
sis of the CARE secondary prevention trial, 15 in which the risk for CVEs was 
correlated with on-treatment plasma LDL-C levels down to a cutoff point of 
-125 mg/dL, below which no further risk reduction was observed. 
In the present report, a statistical analysis was undertaken to explore the rela- 
tionship between reduction in LDL-C level and the prevalence of CVEs and age and 
sex differences in the effectiveness of pravastatin treatment in the PATE study. 12 
MATERIALS AND METHODS 
PATE Study Protocol 
Male and female patients (age range, 62-93 years) with primary hypercholes- 
terolemia were recruited from 52 participating institutions in Japan. Those with 
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familial or secondary hypercholesterolemia and/or malignant neoplasia were 
excluded. 
Because the PATE study was designed in 1990 and started in 1991, before the 
International Conference on Harmonisation Good Clinical Practice guideline 18 
was established, only oral informed consent was obtained from eligible patients 
and noted in the medical records; in addition, institutional review board ap- 
proval of the study protocol was not sought at all of the study sites. Ethical 
aspects of the study were continually examined by the monitoring committee 
within the research organization of the PATE study. 
After oral informed consent had been obtained, patients were randomized to 
the low-dose or the standard-dose group at the randomization center at the 
Department of Biostatistics/Epidemiology and Prevention Health Sciences, 
School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan, by 
telephone or facsimile. Randomization was achieved with the dynamic (adap- 
tive) balancing method (the minimization method with biased coin), using his- 
tory of CVD, TC level, and study site as the balancing factors. 
All antihyperlipidemic medications were discontinued _>3 months before 
study initiation. Twelve-hour fasting serum lipid levels (TC, triglyceride [TG], 
and high-density lipoprotein cholesterol [HDL-C]), blood pressure, and body 
weight were measured before randomization and 1, 3, and 6 months after initia- 
tion of pravastatin treatment and every 6 months thereafter. LDL-C levels were 
calculated using the Friedewald formula. 19 Routine medical examinations, includ- 
ing physical examinations, peripheral blood cell counts, and blood chemistry, 
were conducted by physicians at least every 6 months. Adverse events were 
monitored in conjunction with these visits. Serum lipid levels were determined 
by enzymatic holesterol and TG assays. The accuracy and precision of the mea- 
surement of TC, TG, and HDL-C levels at each study site were assessed in accor- 
dance with the Lipid Standardization Program of the Centers for Disease 
Control and Prevention, Atlanta, Georgia. 2° Levels of accuracy, expressed as 
mean (SD) percentage bias for TC, TG, and HDL-C levels, were -1.78% (2.24%), 
0.57% (6.75%), and 2.04% (6.64%), respectively. Levels of precision, expressed 
as mean (SD) CV for TC, TG, and HDL-C levels, were 0.85 (0.66), 1.39 (2.21), and 
1.85 (1.42), respectively. Adverse events were defined as any unfavorable new 
symptoms, worsening of symptoms existing at baseline, or any unfavorable 
change in laboratory findings. 
Every 3 months during the follow-up period, the doses of study medication 
were reported by mail by the participating physicians. If a patient had discon- 
tinued treatment, his or her physician recorded the discontinuation date and 
the reason(s) for it. 
The primary end point of the PATE study was the incidence of fatal or nonfa- 
tal CVEs, including cerebrovascular disease, ischemic heart disease, peripheral 
vascular disorder, and sudden death. Cerebrovascular disease included cere- 
bral infarction, cerebral hemorrhage, transient ischemic attack, and subarach- 
noid hemorrhage. Coronary heart disease included MI, angina pectoris (AP), 
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congestive heart failure due to coronary heart disease, and arrhythmia requir- 
ing pharmacologic treatment. Secondary end points of the PATE study were the 
combined prevalences of MI and AP and death from all causes. 
Potential end points in the PATE study were reviewed and classified bythe  
Case/Event Evaluation Committee of the study investigators. Members of this 
committee were blinded to the patients' identities and treatment assignments. 
Statistical Analysis 
Cox regression analysis was performed to study the relationship between on- 
treatment LDL-C level and the prevalence of CVEs using age, sex, smoking sta- 
tus, presence of diabetes mellitus (DM) and/or hypertension, history of CVD, 
and HDL-C level as adjustment factors. 21 On-treatment LDL-C and HDL-C levels 
were used as time-dependent covariates. To avoid confounding treatment effect 
and LDL-C level reduction, no dummy variable for treatment group difference 
was included. Time to CVE was measured from the start of drug administration. 
Similar analyses were conducted for the following subgroups: age >_75 years, 
age <75 years, sex, and history of CVD. For ease of interpretation in these analy- 
ses, CVE risk reduction due to LDL-C level modification was calculated from lin- 
ear regression coefficients and expressed as risk reduction (%) per 20-mg/dL 
decrease in LDL-C level. 2 
To explore risk reduction due to unspecified mechanisms other than LDL-C 
reduction, an estimated Kaplan-Meier curve from the Cox regression was calcu- 
lated and compared with the empirical (observed) Kaplan-Meier curve. The 
estimated curve was calculated for each treatment group by averaging esti- 
mated curves for each individual patient using each patient's covariates (prog- 
nostic factors or adjustment factors). The covariates used were age, sex, smok- 
ing status, presence of DM and/or hypertension, history of CVD, the interaction 
between DM and history of CVD, HDL-C level (the last available observation), 
pretreatment LDL-C level, and the difference in LDL-C level between pretreat- 
ment and the last available observation. HDL-C and LDL-C levels were not 
treated as time-dependent covariates because the baseline survival curve 
might not easily be estimated under the existence of time-dependent covari- 
ates. An interaction term was added to increase the model fit, which did not 
change the essential conclusion of the report. 
Estimated Kaplan-Meier and empirical Kaplan-Meier curves are hereafter 
called KM-LDL (standard-dose or low-dose) and KM-empirical (standard-dose or 
low-dose), respectively. Two similarly estimated Kaplan-Meier curves were cal- 
culated for each treatment. The first was calculated by inserting the overall 
mean LDL-C level reduction (36 mg/dL) into the LDL-C level difference for both 
treatment groups (KM-LDL36 [standard ose or low dose]) and the second by 
Cox model, including a dummy variable representing treatment-group differ- 
ence and retaining the other variables in the model (KM-ALL [standard ose 
or low dose]). KM-ALL reflects all treatment effects, including modification of 
LDL-C level and other nonspecified rug effects. Visual comparison between 
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KM-LDL and KM-LDL36 provides aqualitative estimate of the drug effect hrough 
LDL-C level modification. Comparison between KM-ALL and KM-empirical pro- 
vides a goodness-of-fit evaluation of the fitted Cox regression. 2~In a subgroup of 
patients without DM or a history of CVD, 4 Kaplan-Meier curves (KM-empirical, 
KM-LDL, KM-LDL36, and KM-ALL) were calculated for each treatment group. 
Finally, the contributing proportion of LDL-C level modification to risk reduc- 
tion (ratio of risk reduction) was calculated as follows: 
Ratio of risk reduction = [1 -SKM.~ L (0]/[ 1 -SKM.empirical (t)], 
where S is the estimated probability of event-free survival and t is time. Similar 
methods were used by Freedman et a122 and Simes et al. 23 
In all analyses of end points, 2-sided P < 0.05 was considered statistically sig- 
nificant and the CI was set at 95%. All statistical analyses were performed using 
SAS version 8.2 (SAS Institute Inc., Cary, North Carolina). 
RESULTS 
In our previous report, 12 665 patients (527 women, 138 men; mean [SD] age, 
72.8 [5.7] years; mean follow-up, 3.9 years [range, 3-5 years]) were analyzed on 
an intent-to-treat basis. Detailed ata on patient background were presented in
that paper 12 and omitted from this report. Mean body mass index was 23 kg/m 2, 
mean LDL-C level was 165 mg/dL, and mean HDL-C level was 55 mg/dL. Thirty 
percent of patients had DM, 51% had hypertension, and 27% had a history of 
CVDs. During the study, the discontinuation rate was 23.9. 
In this study, the data from 619 patients were analyzed, after excluding the 
data from 30 patients who did not start the test medication and 16 patients for 
whom there were no posttreatment lipid levels available for the analysis (Tables I
and II). In the calculation of model-based Kaplan-Meier curves, data from an 
additional 32 patients were excluded from the LDL-C analysis because there 
were no data on pretreatment LDL levels; hence, the data from 587 patients 
were analyzed. The comparison between Kaplan-Meier curves from the ran- 
domization date (shown in our previous report 12) and from the start of medica- 
tion suggested no essential difference. 
A 20-mg/dL reduction in LDL-C levels was associated with a relative CVE risk 
reduction of 24.7% (hazard ratio [HR] = 0.753; 95% CI, 0.625-0.907; P = 0.003) 
(Table III), which corresponded to a 1.24% risk reduction per 1.0-mg/dL reduc- 
tion in LDL-C level. The risk was reduced by 22.2% in 409 patients aged 
<75 years (FIR = 0.778; 95% CI, 0.598-1.013; P = NS) and 29.9% in 210 patients 
aged >75 years (I-IR = 0.701; 95% CI, 0.526-0.934; P = 0.015) (Table III). The risk 
reductions associated with lowering LDL-C levels by 20 mg/dL were 35.8% in 
men (I-IR = 0.642; 95% CI, 0.453-0.911; P = 0.013) and 19.8% in women (HR = 
0.802; 95?/o CI, 0.645-0.996; P = 0.046). The risk reductions were 32.4% in patients 
without a history of CVD at enrollment (HR = 0.676; 95% CI, 0.525-0.870; P = 
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Table I. Baseline demographic data for 619 elderly Japanese pa- 
tients with hypercholesterolemia. 
Characteristic % 
Sex 
Female 78.7 
Male 21.3 
DM 31.2 
Hypertension 51.4 
History of CVD 26.7 
Current/past smoking 12.9 
DM = diabetes mellitus; CVD = cardiovascular disease. 
Table II. Baseline clinical data for 619 elderly Japanese patients 
with hypercholesterolemia. 
Characteristic Mean (SD) 
Age, y 72.8 (5.6) 
BMI, kg/m 2 23.3 (3.2) 
TC, mg/dL 253.3 (15.4) 
HDL-C, mg/dL 55.4 (15.0) 
LDL-C, mg/dL 165.3 (24.4) 
TG, mg/dL 153.2 (85.8) 
SBP, mm Hg 139.0 (15.7) 
DBP, mm Hg 78.2 (9.4) 
BMI = body mass index; TC = total cholesterol; HDL-C = high-density 
l ipoprotein cholesterol; LDL-C = low-density l ipoprotein cholesterol; TG = 
triglycerides; SBP = systolic blood pressure; DBP = diastolic blood pressure. 
0.002) and 15.1% in those with a history of CVD (FIR = 0.849; 95?/0 CI, 0.630-1.143; 
P= NS). 
The comparison between KM-empirical and KM-LDL in the study population 
is shown in Figure 1A. If the fitted Cox model provides a good approximation, 
the comparison suggests that the observed group difference was only partially 
related to LDL-level modification. Comparison between Figures IA and IB sug- 
gests that the relative risk reduction related to LDL-C level modification was, at 
most, 5% to 15%. Figure 1C suggests that the fitted model provided a good 
approximation to KM-empirical. 
The estimated small contribution of LDL-C level modification is summarized 
in Table IV and corresponds to the findings in Figure IA. 
The fitness of the Cox model was further improved when the analysis was 
restricted to patients without DM or history of CVD (Figure 2A and 2B). F'~mre 2A 
also suggests some small contribution of LDL-C level modification to risk reduction. 
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Table III. Cox regression analysis of risk reduction for cardiovascular events (CVEs) 
associated with lowering low-density lipoprotein cholesterol by 20 mg/dL in 
elderly Japanese patients with hypercholesterolemia in the Pravastatin Anti- 
atherosclerosis Trial in the Elderly. 12 
Hazard 
Risk No. of No. of Risk Ratio 
Factor Patients CVEs Reduction, % (95% CI) P 
Overall 619 58 24.7 0.753 (0.625-0.907) 0.003 
Age, y 
<75 409 29 22.2 0.778 (0.598-1.013) 0.062 
>75 210 29 29.9 0.701 (0.526-0.934) 0.015 
Sex 
Female 487 42 19.8 0.802 (0.645-0.996) 0.046 
Male 132 16 35.8 0.642 (0.453-0.911) 0.013 
History of CVD 
No 454 34 32.4 0.676 (0.525-0.870) 0.003 
Yes 165 24 15.1 0.849 (0.630-1.143) 0.281 
CVD = cardiovascular disease. 
DISCUSSION 
The PATE study, 12 published in 2001, was the first major clinical trial of the 
effects of cholesterol-lowering treatment that specifically targeted elderly indi- 
viduals. It found that pravastatin treatment for hypercholesterolemia in elderly 
Japanese patients was associated with a significant reduction in the risk for 
CVEs and was not associated with any clinically significant adverse events. 
These results have important clinical repercussions. 
Statistical analyses from the present study using time-dependent covariates 
found that cholesterol lowering, as measured using LDL-C level, was achieved 
in patients aged >_75 years (29.9% reduction in the prevalence of CVEs, P = 
0.015). In patients aged <75 years, the reduction in CVEs was 22.2%; although 
not statistically significant at conventional levels, this reduction was practically 
and clinically important. The findings were also significant in patients without 
a history of CVD but not in patients with a history of CVD. However, the statis- 
tical power in the subgroup of patients with a history of CVD was diminished 
because of the small size of the group (n = 165). Therefore, the reduction might 
be clinically important and, if found in a larger sample, might indicate that 
the finding was significant. However, the difference in the risk for CVEs 
between the standard-dose and low-dose groups was likely related to a mech- 
anism in addition to LDL-C level attained or the modification of LDL-C level. 
Estimated Kaplan-Meier curves calculated from Cox regression, adjusting for 
other prognostic factors, suggest that the contribution of lowering LDL-C 
level to risk reduction was only 18.4% to 48.5% in 1 to 3 years of follow-up. 
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(A) Estimated Kaplan-Meier low-density lipoprotein (KM-LDL) and empiri- 
cal Kaplan-Meier (KM-empirical) curves and (B) estimated Kaplan-Meier 
(KM-LDL36) and KM-empirical curves for the standard-dose (S) and low- 
close (L) pravastatin groups. KM-LDL was estimated from Cox regression 
using age, sex, smoking status, diabetes mellitus (DM), hypertension, his- 
tory of cardiovascular disease (CVD), interaction between DM and history 
of CVD, high-density lipoprotein cholesterol level (last available observa- 
tion), pretreatment low-density lipoprotein cholesterol (LDL-C) level, and 
difference in LDL-C level between pretreatment and the last available 
observation. KM-LDL36 was estimated from Cox regression in the same way 
as KM-LDL, but 36 mg/dL was inserted as the LDL-C difference. 
(continued) 
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Figure 1. 
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(Continued) (C) Estimated Kaplan-Meier (KM-ALL) and KM-empirical curves 
for the standard-dose (S) and low-dose (L) pravastatin groups. KM-ALL was 
estimated from Cox regression in the same way as KM low-density lipoprotein, 
including the group difference. 
Table IV. Contribution of low-density l ipoprotein cholesterol (LDL-C) reduction to the 
relative risk for cardiovascular events in elderly Japanese patients with 
hypercholesterolemia in the Pravastatin Anti-atherosclerosis Trial in the 
Elderly 12 (n = 587). 
Year of Follow-Up 
Parameter 1 2 3 4 
Risk ratio, observed* 0.509 0.420 
Risk ratio, estimated t 0.892 0.893 
Contribution of LDL-C reduction, %~ 21.9 18.4 
0.579 0.785 
0.894 0.896 
25.2 48.5 
*Calculated by empirical Kaplan-Meier curve. 
tCalculated by estimated Kaplan-Meier curve using Cox regression. 
~Calculated as (1 - estimated risk ratio)/(1 - observed risk ratio) x 100. 
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Figure 2. 
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(A) Estimated Kaplan-Meier low-density lipoprotein (KM-LDL) and empirical 
Kaplan-Meier (KM-empirical) curves and (B) estimated Kaplan-Meier 
(KM-ALL) and KM-empirical curves in patients without diabetes mellitus (DM) 
or history of cardiovascular disease (CVD). KM-LDL was estimated from Cox 
regression using age, sex, smoking status, DM, hypertension, history of 
CVD, interaction between DM and history of CVD, high-density lipoprotein 
cholesterol level (last available observation), pretreatment low-density 
lipoprotein cholesterol (LDL-C) level, and difference in LDL-C level between 
pretreatment and the last available observation. KM-ALL was estimated 
from Cox regression in the same way as KM-LDL, including the group 
difference. S = standard-dose pravastatin group; L = low-dose pravastatin 
group. 
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These results correspond to those derived in previous trials conducted in 
nonelderly white populations. 14,15 
The risk reduction associated with lowering the LDL-C level seemed attenu- 
ated in women compared with men, although the interaction was not statistically 
significant. Sex-related ifferences in the effects of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors ("statins') remain unclear because only small 
numbers of women have been included in intervention trials. 24 Meta-analyses 
have suggested that risk reduction is comparable in men and women 2s and is 
not significant in women without CVD. 24 Because women have lower risk for 
CVEs than do men at any age, 26 the observed effects of statins might be weak- 
ened by the relatively small number of events that occur in female patients dur- 
ing limited follow-up periods. Given the sex-specific effects of statins, the im- 
pact on clinical outcome and underlying mechanism should be addressed inthe 
future. 
The estimated relative risk reduction related to modification of LDL-C level 
in the standard-dose group versus the low-dose group was calculated to be 
12.4% (1.24%/mg/dL × 10 mg/dL) based on the results in Table III and the mean 
difference in LDL-C levels between the 2 groups. This finding corresponds well 
with the estimates from Figures 1A and 1B, a result that was theoretically 
expected because both estimates were derived from similar Cox models. 
One possible explanation for the difference in CVE rates observed between 
the low- and standard-dose groups might be that statins, including pravastatin, 
have several lipid-lowering-independent effects other than reduction of plasma 
cholesterol levels. 27 In the subanalysis of WOSCOPS, 14 CVE rates in the overlap 
area of LDL-C level of 150 to 170 mg/dL in the placebo and pravastatin groups 
were 9.6% (108/1120) and 6.3% (67/1071), respectively (P = 0.002). This result 
suggests that some independent effects of pravastatin in addition to LDL-C 
reduction contribute to reducing the CVE rate. Other clinical studies have sug- 
gested that pravastatin confers everal lipid-lowering-independent antiathero- 
sclerotic effects, such as plaque stabilization, 28 anti-inflammation, 29 and anti- 
thrombosis. 3° Improvement of endothelium-dependent coronary vasomotion 31 
and antiatherosclerotic effect possibly associated with anti-inflammatory effect 32 
have also been documented. These observations suggest hat pravastatin 
has cholesterol-lowering-independent effec s that might contribute to its anti- 
atherosclerotic effects. In the near future, results of a large-scale, controlled 
clinical study of the effects of pravastatin Japanese patients 33 with hypercho- 
lesterolemia will become available. The results of the PATE study will be re- 
examined in light of these new data. 
CONCLUSIONS 
The results from this post hoc analysis uggest hat pravastatin 5 to 20 mg/d 
might elicit CVE risk reduction by mechanisms other than cholesterol-lowering 
effects alone. They also suggest that pravastatin treatment might be effective in 
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reducing the risk for CVEs in patients aged >_75 years and in both female and 
male patients. 
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